\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}



\usepackage{float}








\begin{document}

\title{Loss of Anti-Spike Antibodies Following mRNA Vaccination for COVID-19
Among Patients with Multiple Myeloma}



\author[1]{Samuel D. Stampfer}%
\author[2]{Sean Bujarski}%
\author[2]{Merissa-Skye Goldwater}%
\author[2]{Scott Jew}%
\author[3]{Bernard Sean Regidor}%
\author[2]{Haiming Chen}%
\author[2]{Ning Xu}%
\author[2]{Mingjie Li}%
\author[3]{Eddie Fung}%
\author[3]{Regina A. Swift}%
\author[3]{Bethany Beatty}%
\author[4]{Shahrooz Eshaghian}%
\author[2]{James Berenson, MD, Inc.}%
\affil[1]{Emory University}%
\affil[2]{Institute for Myeloma and Bone Cancer Research}%
\affil[3]{Berenson Cancer Center West Hollywood CA­}%
\affil[4]{Cedars Sinai Medical Center Division of Hematology and Oncology Los Angeles CA}%


\vspace{-1em}



  
  \date{May 18, 2024}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup





\selectlanguage{english}
\begin{abstract}
\textbf{Background} Multiple myeloma (MM) patients have variable
responses to mRNA vaccination to COVID-19. Little is known regarding
their vaccine-induced antibody levels over time. \textbf{Methods} We
monitored spike IgG antibody levels over 24 weeks among a subset of 18
MM patients who showed a full response after two mRNA vaccinations. MM
patients had a more rapid decline in antibody levels as compared to 8
healthy controls, with power law half-lives of 72 days (versus 107 days)
and exponential half-lives of 37 days (versus 51 days). \textbf{Results}
The patients with longer SARS-CoV-2 antibody half-lives were more likely
to have undetectable monoclonal protein than those with shorter
half-lives, suggesting better disease control may correlate with longer
duration of vaccine-induced antibodies. Regardless, by 16 weeks
post-second dose of mRNA vaccination, the majority of patients had
antibody levels below 250 binding arbitrary units per milliliter, which
would be unlikely to contribute significantly to preventing COVID-19.
\textbf{Conclusions} Thus, even MM patients who respond adequately to
vaccination are likely to require more frequent booster doses than the
general population.%
\end{abstract}%



\sloppy


\textbf{Hosted file}

\verb`EJH Manuscript v5.docx`  available at \url{https://authorea.com/users/525602/articles/595938-loss-of-anti-spike-antibodies-following-mrna-vaccination-for-covid-19-among-patients-with-multiple-myeloma}

\selectlanguage{english}
\FloatBarrier
\end{document}

